Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-08-29
2006-08-29
Saoud, Christine J. (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S193100, C424S184100, C424S278100, C514S002600, C530S300000, C530S350000
Reexamination Certificate
active
07097837
ABSTRACT:
The present invention provides for novel immungens that are comprised of an activated polyhydroxypolymer backbone to which is attached 2 separate antigenic determinants. The 1st antigenic determinant includes a B-cell or CTL epitope and the 2nd antigenic determinant includes a T-helper epitope. In preferred embodiments, the antigenic determinants are derived from different molecules and species. Exemplary immunogens of the invention are constituted of a linear tresyl-activated dextran backbone to which is coupled B-cell or CTL epitopes of an antigen and to which is also coupled universal T-helper epitopes. Also disclosed are immunogenic compositions comprising the immunogens, methods of immunization and a method for identification of suitable immunogens of the invention.
REFERENCES:
patent: 4578770 (1986-03-01), Mitani
patent: 4596792 (1986-06-01), Vyas
patent: 4599230 (1986-07-01), Milich et al.
patent: 4599231 (1986-07-01), Milich et al.
patent: 4601903 (1986-07-01), Frasch
patent: 4608251 (1986-08-01), Mia
patent: 5200339 (1993-04-01), Abraham et al.
patent: 5223482 (1993-06-01), Schilling, Jr. et al.
patent: 5573916 (1996-11-01), Cheronis et al.
patent: 5709995 (1998-01-01), Chisari et al.
patent: 5780036 (1998-07-01), Chisari
patent: 5874469 (1999-02-01), Maniar et al.
patent: 6713450 (2004-03-01), Frangione et al.
patent: 6787523 (2004-09-01), Schenk
patent: 6787637 (2004-09-01), Schenk
patent: 2002/0077288 (2002-06-01), Frangione et al.
patent: 2004/0062802 (2004-04-01), Hermelin et al.
patent: 2004/0091945 (2004-05-01), Fitzer-Atlas et al.
patent: 93/15760 (1993-08-01), None
patent: WO 93/15760 (1993-08-01), None
patent: 93/23076 (1993-11-01), None
patent: WO 93/23076 (1993-11-01), None
patent: WO 94/03530 (1994-02-01), None
patent: WO 95/05849 (1995-03-01), None
patent: WO 95/07707 (1995-03-01), None
patent: 96/13513 (1996-05-01), None
patent: WO 98/23635 (1998-06-01), None
patent: WO 00/05316 (2000-02-01), None
patent: WO 00/20027 (2000-04-01), None
patent: WO 00/65058 (2000-11-01), None
Skolnick & Fetrow (2000) “From genes to protein structure and function: novel applications of computational approaches in the genomic era.” Trends in Biotech. 18(1): 34-39.
Jobling & Holmes (1991) “Analysis of structure and function of the B Subunit of cholera toxin by the use of site-directed mutagenesis.” Molecular Microbiology 5(7): 1755-67.
Calvo-Calle et al. (Feb. 15, 1993) “Immunogenicity of Multiple Antigen Peptides Containing B and Non-Repeat T cell Epitopes of Circumsporozoite Protein of Plasmodium falciparum.” The Journal of Immunology 150(4): 1403-1412.
Calvo-Calle et al. (Feb. 15, 1993) “Immunogenicity of Multiple Antigen Peptides Containing B and Non-Repeat T cell Epitopes of the Circumsporozoite Protein of Plasmodium falciparum.” The Journal of Immunology 150(4): 1403-1412.
Sela et al. (Apr. 1992) “A Tale of Two Peptides, TyrTyrGluGlu and TyrGluTyrGlu, and their Diverse Immune Behavior.” Behring Inst. Mitt. 91: 54-66.
Goldsby et al. (2002) Kuby Immunology Chapter 1 “Overview of the Immune System” (pp. 3-25).
Goldsby et al. (2002) Kuby Immunology Chapter 18 “Vaccines” (pp. 449-465).
Gregorius and Theisen, “In Situ Deprotection: A method for Covalent Immobilization of Peptides with well-defined orientation for use in solid phase immunoassays such as enzyme-linked immunosorbent assay” (2001) Analytical Biochemistry 299:84-91.
Barr and Mitchell, “ISCOMs (immunostimulating complexes): The first decade ” Immunology and Cell Biology (1996) 74: 8-25.
Gosselin et al. “Enhanced Antigen Presentation using Human Fc□ Receptor(Monocyte/Macrophage)-specific immunogens” (1992) 149:3477-3481.
Nilsson and Mosbach (1987) “Supports for Enzyme Immobilization ” Methods in Enzymology 135: 67.
Hemansson et al. “Immobilized affinity ligand techniques ” (1992) 87.
Morein et al. “Immunostimulating Complexes, Clinical Potential Vaccine Development” Clin. Immunotherapy (1995) 3(6): 460-475.
Irving et al. “Random-peptide libraries and antigen-fragment libraries for epitope mapping and the development of vaccines and diagnostics” Current Opinion in Chemical Biology (2001) 5:314-324.
Nelson et al. “Monoclonal antibodies” Molecular Pathology, Accepted for publication Feb. 8, 2000.
Nussinov and Wolfson, Efficient Computational Algorithms for Docking and for generating and matching a library of functional epitopes II. Computer Vision-based techniques for the generation and utilization of functional epitopes. (1999) Combinatorial Chemistry and High Throuput Screening 2: 261-269.
De Groot et al. “From genome to vaccine: in silico predictions, ex vivo verification” Vaccine 19 (2001) 4385-4395.
Rammensee et al. “MHC ligands and peptide motifs: first listings” Immunogenetics (1995) 41: 178-228.
Schirle et al. “Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach” Eur. J. immunol, (2000) 30: 2216-2225.
Southwood et al. “Several Common HLA-DR Types share largely overlapping peptide binding repertoires” The Journal of Immunology, 1998, 160: 3363-3373.
Singigaglia et al. “A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules” Nature vol. 336 Dec. 22-29 1988, 778-780.
Chicz et al. “Specificity and Promiscuity among naturally processed peptides bound to HLA-DR Alleles” (1993) J. Exp. Med. 178: 27-79.
Hammer et al. “Promiscuous and Allele-specific anchors in HLA-DR-Binding Peptides” (1993) Vell, vol. 197-203.
Falk et al. “Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing and general rules” Immmunogenetics (1994) 39: 230-242.
Alexander et al. “Serum interleukin 5 concentrations in atopic and non-atopic patients with glucocorticoid-dependent chronic severe asthma” Thorax (1994) 49:1231-1233.
Dempsey et al. “C3d of complement as a molecular adjuvant: bridging innate and acquired immunity” (1996) Science 271: 348.
Lou and Kohler, “Enhanced molecular mimicry of CEA using photoaffinity crosslinked C3d peptide” Nature Biotechnology (1998) 16: 458-462.
Gregorius et al. “Hydrocoating: a new method for coupling biomolecules to solid phases” Journal of Immunological Methods (1995) 181:65-73.
Calvo-Calle, et al.; “Immunogenicity of Multiple Antigent Peptides Containing B and Non-Repeat T cell Epitose of the Circumsporozoite Protein of Plaemodium Falciparum”; The Journal of Immunology (1993); vol. 150(4); pp. 1403-1412.
Goldsby, et al.; “Overview of the Immune System”; Kuby Immunology (2002); Chapter 3; pp. 3-25.
Goldsby, et al.; “Vaccines”; Kuby Immunology(2002); chapter 18; pp. 449-465.
Lees, et al.; “Enhanced Immunogenicity of Protein-Dextran Conjugates: I. Rapid Stimulation of Enhanced Antibody responses to Poorly Immunogenic Molecules:”; Vaccine(1994); vol. 12(13); pp. 1160-1166.
Marguerite, M., et al; “Analysis of Antigenicity and Immunogenicity of five Different Chemically Defined Constructs of a Peptide”; Molecular Immunology(1992); vol. 29(6): pp. 793-800.
Otvos, et al.; “In Situ Stimulation of a T Helper cell Hybridoma with a Cellulose-bound peptide Antigen”; Journal of Immunological Methods(2000); vol. 233 (1-2); pp. 95-105.
Sela, et al.; “A tale of Two Peptides, TyrtyrGluGlu and TryGluTyrGlu, and their diverse Immune Behavior”; Behring Inst. Mitt. vol. 91; pp. 54-66.
Koefoed Peter
Nielsen Klaus Gregorius
Lockard Jon M.
Pharmexa A/S
Saoud Christine J.
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Synthetic vaccine agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthetic vaccine agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic vaccine agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3691773